3-Jan-2025
No headlines found.
Globe Newswire (Thu, 19-Dec 7:00 AM ET)
Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)
Globe Newswire (Wed, 18-Dec 7:00 AM ET)
Oruka Therapeutics to Present at Piper Sandler's 36th Annual Healthcare Conference
Globe Newswire (Tue, 19-Nov 8:00 AM ET)
Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Globe Newswire (Wed, 13-Nov 4:25 PM ET)
Oruka Therapeutics to Present at Multiple November Investor Conferences
Globe Newswire (Mon, 4-Nov 7:00 AM ET)
Oruka Therapeutics Inc is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. It is to offer patients suffering from chronic skin diseases like plaque psoriasis.
Oruka Therapeutics trades on the NASDAQ stock market under the symbol ORKA.
As of January 3, 2025, ORKA stock price climbed to $20.81 with 192,843 million shares trading.
ORKA has a beta of 0.51, meaning it tends to be less sensitive to market movements. ORKA has a correlation of 0.01 to the broad based SPY ETF.
ORKA has a market cap of $728.32 million. This is considered a Small Cap stock.
The top ETF exchange traded funds that ORKA belongs to (by Net Assets): IBB, ITOT, VTI, VXF, IWC.
ORKA support price is $18.80 and resistance is $21.14 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ORKA shares will trade within this expected range on the day.